和肽素联合TIMI评分对急性ST段抬高型心肌梗死合并心力衰竭患者预后的评估价值OA
The Evaluation Value of Peptide Combined with TIMI Score for the Prognosis of Patients with Acute ST-Segment Elevation Myocardial Infarction Complicated with Heart Failure
目的:探讨血清和肽素(copeptin)水平联合心肌梗死溶栓治疗危险评分(TIMI)对急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)合并心力衰竭(heart failure,HF)患者预后的评估价值.方法:选取 107 例确诊急性心肌梗死后HF患者进行TIMI评分,根据评分结果分为低危组(0~3 分)31 例,中危组(4~6 分)42 例,高危组(7~14 分)34 例.根据copeptin水平分为低copeptin组 60 例及高copeptin组 47例.比较TIMI低、中、高危组患者及低、高copeptin组患者出院后180 d内再发/未发生主要心脏不良事件(major adverse cardiovascular events,MACE)患者的血清copeptin水平及TIMI评分.结果:低、中、高危组患者血清copeptin水平分别为(17.59±3.06)、(22.76±5.01)、(43.04±11.55)pmol·L-1,copeptin水平随着TIMI评分上升而升高,差异有统计学意义(P<0.05).出院后随访 180 d,再发MACE者 29 例,未发生MACE者 78 例;再发MACE者血清copeptin水平明显高于未发生MACE者的[(40.70±12.22)vs(20.13±4.92)pmol·L-1,P<0.05];再发MACE者的TIMI评分明显高于未发生MACE者[(8±4)vs(5±3)分,P<0.05].180 d临床随访期间,高copeptin组心源性死亡累积发生率高于低copeptin组(P<0.05).结论:血清copeptin联合TIMI评分对STEMI合并HF患者预后评估具有积极临床参考价值.
Objective:To investigate the prognostic value of serum copeptin level combined with thrombolysis in myocardial infarction(TIMI)score in patients with acute ST-segment elevation myocardial infarction(STEMI)complicated with heart failure(HF).Methods:A total of 107 patients with HF after acute myocardial infarction were selected for TIMI score.According to the score results,they were divided into low-risk group(0~3 points)with 31 cases,medium-risk group(4~6 points)with 42 cases,and high-risk group(7~14 points)with 34 cases.According to the level of copeptin,they were divided into low copeptin group(60 cases)and high copeptin group(47 cases).The serum copeptin levels and TIMI scores of patients with low,medium and high-risk groups of TIMI and patients with low and high copeptin groups with recurrence/no MACE within 180 days after discharge were compared.Results:The levels of serum copeptin in the low,medium and high-risk groups were(17.59±3.06),(22.76±5.01)and(43.04±11.55)pmol·L-1,respectively.The level of copeptin increased with the increase of TIMI score,and the difference was statistically significant(P<0.05).After 180 days of follow-up,there were 29 cases of major adverse cardiac events(MACE)and 78 cases without MACE.The serum copeptin level in patients with recurrent MACE was significantly higher than that in patients without MACE[(40.70±12.22)vs(20.13±4.92)pmol·L-1,P<0.05].The TIMI score of patients with recurrent MACE was significantly higher than that of patients without MACE[(8±4)vs(5±3),P<0.05].During the 180-day clinical follow-up,the cumulative incidence of cardiac death in the high copeptin group was higher than that in the low copeptin group(P<0.05).Conclusion:Serum copeptin combined with TIMI score has positive clinical reference value for prognosis evaluation of STEMI patients with HF.
王子帅;东野鸿方;刘加齐;李方江
河北北方学院 研究生学院,张家口,075000,中国河北北方学院 研究生学院,张家口,075000,中国河北北方学院 研究生学院,张家口,075000,中国河北北方学院附属第一医院心血管内科,张家口,075000,中国
医药卫生
和肽素心肌梗死溶栓治疗危险评分ST段抬高型心肌梗死心力衰竭生物标志物
copeptinTIMI risk score for myocardial infarction thrombolytic therapySTEMIheart failurebiomarker
《神经药理学报》 2026 (1)
23-27,5
评论